医学
阿替唑单抗
肝细胞癌
危险系数
内科学
贝伐单抗
胃肠病学
肿瘤科
子群分析
肝癌
癌症
化疗
置信区间
无容量
免疫疗法
作者
Toshifumi Tada,Takashi Kumada,Atsushi Hiraoka,Masashi Hirooka,Kazuya Kariyama,Joji Tani,Masanori Atsukawa,Koichi Takaguchi,Ei Itobayashi,Shinya Fukunishi,Hiroki Nishikawa,Kunihiko Tsuji,Toru Ishikawa,Kazuto Tajiri,Yuichi Koshiyama,Hidenori Toyoda,Chikara Ogawa,Takeshi Hatanaka,Satoru Kakizaki,Kazuhito Kawata
摘要
Atezolizumab plus bevacizumab (Atezo/Bev) is frequently selected as the primary systemic therapy for hepatocellular carcinoma (HCC).
科研通智能强力驱动
Strongly Powered by AbleSci AI